GlassScriptPhysician profile
Harold K Wong
NPI 1528357175
$4,071.63
in general payments reported to CMS, 2019-2025
27 companies · $999 in 2025
The $999 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $581 · 2022: $574 · 2023: $1,025 · 2024: $893 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,917.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $802.69 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $653.84 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $595.83 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $343.57 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $200.56 | 2021-2023 | Verquvo, Belsomra |
| Exact Sciences Corporation | $167.82 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $152.70 | 2023-2024 | Quviviq |
| Pfizer INC. | $143.52 | 2021-2025 | |
| Eisai INC. | $130.21 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.80 | 2021-2024 | Jardiance |
| Glaxosmithkline, LLC. | $96.67 | 2021-2024 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $83.93 | 2022 | |
| Esperion Therapeutics, INC. | $75.86 | 2021 | |
| Phathom Pharmaceuticals, INC. | $74.31 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $62.84 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $50.86 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $49.79 | 2025 | Rexulti |
| Amgen INC. | $48.59 | 2021 | |
| Novartis Pharmaceuticals Corporation | $47.90 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $35.33 | 2021 | |
| Sumitomo Pharma America, INC. | $28.98 | 2025 | Gemtesa |
| Vertex Pharmaceuticals Incorporated | $27.68 | 2025 | |
| Lucid Diagnostics INC. | $27.14 | 2022 | |
| Gilead Sciences, INC. | $25.51 | 2023 | |
| Paratek Pharmaceuticals, INC. | $23.14 | 2025 | Nuzyra |
| Janssen Pharmaceuticals, INC | $16.81 | 2023 | Xarelto |
| Genentech USA, INC. | $5.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.